Loading…
For subclinical hypothyroid with symptoms: defensible. For asymptomatic optimization: outpaces the evidence.
Treating subclinical hypothyroidism in older adults has not improved hard outcomes in trials.
Our read is Limited Research. The mechanistic story is plausible and the early signals are interesting, but the human outcome data is thin: a limited evidence base (42/100) and only thin support (38% consensus). At $15/month, pushing TSH below 2.5 with levothyroxine is a bet on preliminary science rather than a settled recommendation.
Pulled the public claims about pushing TSH below 2.5 with levothyroxine from the proponents circulating the claim and weighed them against the more cautious voices (a tracked voice), then cross-checked each against the primary trial and cohort literature and the prevailing clinical guidance. We grade the claim against what the human evidence actually supports, not against how confidently it is stated.
This carries medium risk: interactions, contraindications, and dose sensitivity all matter, so pushing TSH below 2.5 with levothyroxine is not a casual decision. Loop in a clinician who can see your full history before starting.
A well-designed human outcome trial — the kind that currently does not exist — demonstrating benefit at the doses people actually use.
Benefits hold across the populations where it's been tested.
The intervention improves the primary outcome at standard doses in healthy adults.
The effect size is large enough to matter clinically, not just statistically.
The intervention improves the primary outcome at standard doses in healthy adults.
Mechanistic and trial evidence converge on a real, replicable effect.
Animal-model results don't translate to the human protocol being recommended.
Confounding and publication bias inflate the apparent benefit.
The headline effect shrinks once you account for trial quality.
Confounding and publication bias inflate the apparent benefit.
Confounding and publication bias inflate the apparent benefit.